What's New with CLL Treatments w/Top Expert | Dr. William Wierda, MD Anderson | The Patient Story

(27:49)

Dr. Wierda on the Need for Continuous Treatment for CLL

(57)

Dr. Wierda on Frontline Therapy for Older CLL Patients Compared to Younger

(2:13)

Dr. Wierda on Chemoimmunotherapy in CLL

(1:57)

Dr. Wierda Discusses Sequencing New Agents in CLL

(1:15)

Dr. Wierda Discusses the Need for Newer Therapies in CLL

(1:13)

Dr. Wierda on Treatment of Relapsed/Refractory CLL

(1:58)

Hormesis \u0026 Plant Toxins - When Doctors Go To War (Dr Idz Vs Chaffee)

(12:33)

Medical Witnesses to a War of Extermination

(55:18)

Dr. Datis Kharrazian interviews Andrew Campbell, MD, on the known medical science about Mycotoxins

(1:2:33)

ADHD and Neurodivergence: Hypermobility, Mold and a Dysregulated Nervous System - Dr. Aaron Hartman

(53:23)

The POTScast E142: Unraveling Medical Complexities with Drs. David Kaufman and Ilene Ruhoy

(47:28)

How do monoclonal antibodies work? Rituximab, infliximab, adalimumab and others

(11:49)

Chia seeds, Healthy Or Fad?

(2:14)

Chronic Lymphocytic Leukemia Treatment \u0026 Side Effects (Venetoclax \u0026 Obinutuzumab) | Tamsin (3 of 3)

(17:13)

\

(17:1econd)

Leukemia Patient Story: My 1st Symptoms for CLL | Stephen's Story (1/5) | The Patient Story

(10:30)

Dr. Wierda on Frontline Management of Patients With CLL

(1:10)

Dr. Wierda Discusses the Role of Ibrutinib in CLL

(1:25)

Dr. Wierda on Combination Regimens With Venetoclax in CLL

(1:42)

Dr. Wierda on Targeted Therapies for CLL

(2:42)

Dr. Wierda on Treatment Recommendations for Elderly Patients With CLL

(1:43)

Dr. Wierda Discusses Use of CAR T Cells in CLL

(1:26)

Dr. Wierda on Immunotherapy Agents for Patients With CLL

(1:2)

Dr. Wierda on Ibrutinib Plus Venetoclax in CLL

(1:16)

Dr. Wierda on Factors to Consider in Frontline Management of CLL

(2:7)

Dr. Wierda on Role of Rituximab Biosimilar in Evolving CLL Treatment Paradigm

(1:39)

Dr. Wierda on Ibrutinib Resistance in CLL

(2:11)

Dr. William G. Wierda on Role for Ibrutinib in Frontline CLL

(1:38)